BioCentury
ARTICLE | Company News

Intas Pharmaceuticals sales and marketing update

May 4, 2015 7:00 AM UTC

Intas launched Intacept, a biosimilar of autoimmune Enbrel entanercept, in India. Intas says that Intracept cuts the cost of treatment “to about half” compared to Enbrel from Amgen Inc. (NASDAQ:AMGN...